Evidence map›Paper›PMID 41720881›Full record

ArticleScientific reports2026

ABE9 fused to SpRY Cas9 nickase enables precise generation of bystander free mouse models.

Jun Kai Ong, Sayari Bhunia, Beate Hilbert, Vanessa Kirschner, Sascha Duglosz, Frank Zimmermann, Marc Freichel, Alex Cornean

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. TPC1-dependent control of endosomal pH and transferrin uptake determines cellular iron status.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jun Kai OngInstitute of Pharmacology, Heidelberg University, 69120, Heidelberg, Germany.ORCID http://orcid.org/0009-0005-1865-9465
Sayari BhuniaInstitute of Pharmacology, Heidelberg University, 69120, Heidelberg, Germany.
Beate HilbertInstitute of Pharmacology, Heidelberg University, 69120, Heidelberg, Germany.
Vanessa KirschnerInstitute of Pharmacology, Heidelberg University, 69120, Heidelberg, Germany.
Sascha DugloszInterfacultary Biomedical Faculty (IBF), Heidelberg University, 69120, Heidelberg, Germany.
Frank ZimmermannInterfacultary Biomedical Faculty (IBF), Heidelberg University, 69120, Heidelberg, Germany.
Marc FreichelInstitute of Pharmacology, Heidelberg University, 69120, Heidelberg, Germany. marc.freichel@pharma.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-1387-2636
Alex CorneanInstitute of Pharmacology, Heidelberg University, 69120, Heidelberg, Germany. alex.cornean@pharma.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-3727-7057

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Point mutations cause many genetic disorders, but modelling them in organisms is technically challenging. Creating mouse models that mimic these mutations is crucial for establishing a causal relationship between mutations and disease phenotype, thereby supporting the development of therapeutic strategies. Adenine base editors (ABEs) can correct single-nucleotide variants (SNVs) in disease modelling without double-stranded breaks (DSBs) or donor DNA, achieving higher product purity than traditional Cas9 methods. Earlier ABE techniques faced issues like limited targetability, bystander editing, and off-target effects. By combining two editor advancements, we introduced and tested ABE9-SpRY, an improved ABE variant fused with a PAM-flexible SpRY-Cas9 nickase. Our results show that ABE9-SpRY effectively generates three out of four targeted A-to-G mutations in mouse embryos, achieving desired editing efficiencies of up to 96% in individual adult founder mice. Furthermore, we observe fewer off-target events at predicted DNA sites in mouse embryos and in an orthogonal R-loop assay compared with ABE8e-SpRY. ABE9-SpRY also enhances product purity in mouse embryos under pooled sgRNA injections and, as a proof-of-concept, at a single endogenous locus in human induced pluripotent stem cells (hiPSCs), relative to ABE8e-SpRY. Our findings support ABE9-SpRY's precision at the loci tested and PAM-flexible versatility. Although performance remains sequence-dependent, these data support ABE9-SpRY as a PAM-flexible tool for generating precise point-mutation models where bystander editing is a concern.

Indexed as

CRISPR-Associated Protein 9CRISPR-Cas SystemsDeoxyribonuclease IGene EditingAnimalsHumansMicePoint MutationCRISPR-Associated Protein 9Deoxyribonuclease IAdenine base editingCRISPR-Cas9hiPS cellsMouse modellingPrecision editing

Identifiers

PMID41720881
PMCPMC12929607

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.